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Purpose: To evaluate patient selection criteria, methodology, safety and clinical outcomes of stereotactic body
radiotherapy (SBRT) for treatment of vertebral metastases.
Materials and methods: Eight centers from the United States (n = 5), Canada (n = 2) and Germany (n = 1)
participated in the retrospective study and analyzed 301 patients with 387 vertebral metastases. No patient had
been exposed to prior radiation at the treatment site. All patients were treated with linac-based SBRT using
cone-beam CT image-guidance and online correction of set-up errors in six degrees of freedom.
Results: 387 spinal metastases were treated and the median follow-up was 11.8 months. The median number of
consecutive vertebrae treated in a single volume was one (range, 1-6), and the median total dose was 24 Gy
(range 8-60 Gy) in 3 fractions (range 1-20). The median EQD210 was 38 Gy (range 12-81 Gy). Median overall survival (OS)
was 19.5 months and local tumor control (LC) at two years was 83.9%. On multivariate analysis for OS, male sex
(p < 0.001; HR = 0.44), performance status <90 (p < 0.001; HR = 0.46), presence of visceral metastases (p = 0.007;
HR = 0.50), uncontrolled systemic disease (p = 0.007; HR = 0.45), >1 vertebra treated with SBRT (p = 0.04; HR = 0.62) were
correlated with worse outcomes. For LC, an interval between primary diagnosis of cancer and SBRT of ≤30 months
(p = 0.01; HR = 0.27) and histology of primary disease (NSCLC, renal cell cancer, melanoma, other) (p = 0.01; HR = 0.21)
were correlated with worse LC. Vertebral compression fractures progressed and developed de novo in 4.1% and
3.6%, respectively. Other adverse events were rare and no radiation induced myelopathy reported.
Conclusions: This multi-institutional cohort study reports high rates of efficacy with spine SBRT. At this time the
optimal fractionation within high dose practice is unknown.Introduction
A single fraction of conventional radiotherapy with 8 Gy
has been recommended for painful vertebral metastases
[1-3]. However, this conventional radiotherapy is associ-
ated with only short term pain relief of 3 – 6 months.
This might be sufficient for metastatic patients with
short life expectancy. However, today validated scores* Correspondence: Matthias.Guckenberger@usz.ch
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article, unless otherwise stated.are available to select a subgroup of patients with longer
overall survival [4]. In parallel, improvements of overall
survival due to more effective systemic treatments in
many cancer types motivated the evaluation of radiation
technology to maximize pain control and local control
for the long term. With image guidance (IGRT), inten-
sity modulated radiotherapy (IMRT), precision patient
positioning devices and a fundamental shift in our un-
derstanding of the radiobiology of high dose radiation,
Stereotactic Body Radiotherapy (SBRT) has emerged for
the treatment of spinal metastases.
SBRT achieves local tumor control rates exceeding
90% in early stage non-small cell lung cancer (NSCLC).Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Guckenberger et al. Radiation Oncology 2014, 9:226 Page 2 of 8
http://www.ro-journal.com/content/9/1/226The methodology of image-guided SBRT was trans-
ferred from lung cancer to vertebral metastases aiming
at more rapid and especially long-term pain and tumor
control by more intense irradiation [5]. Spine SBRT
was quickly adopted in the radiotherapy community
[6]. However, this broad clinical implementation is
supported by only few prospective trials [7,8]: evidence is
mostly based on small, retrospective, and single-institution
analyses.
Although the risk of radiation induced myelopathy is
low after spine SBRT [9,10], unexpectedly high rates
of “new” toxicities like vertebral compression fracture
have been described [11]. These observations combined
with a lack of standardization of spine SBRT practice
indicate that larger studies with longer follow-up as
well as prospective trials are required to establish the
methodology and value of SBRT in the multidisciplinary
management of spinal metastases. Therefore, it was
the aim of this study to establish a multi-institutional
database of spine SBRT and to analyze patient selec-
tion criteria, methodology, safety and clinical outcome
after spine SBRT.
Materials and methods
Eight international centers from the United States (n = 5),
Canada (n = 2) and Germany (n = 1) participated in this
retrospective study. The local ethics committee ap-
proved participation in this study in all eight centers.
The study is based on 301 patients treated for 387 ver-
tebral metastases (11 to 118 per institution) between
2004 and 2013; 370 of 387 SBRT treatments were per-
formed 2008 and later.
A homogeneous patient cohort was analyzed in this
study: SBRT was used as re-irradiation in none of the
cases and no patient suffered from symptomatic spinal
cord compression. All centers are members of the
“Elekta Spine SBRT Research Consortium” and there-
fore, identical treatment delivery technology was used in
all treatments. Patients were treated with linac based
SBRT using daily cone-beam CT based image-guidance,
online correction of set-up errors in six degrees of free-
dom using the robotic HexaPod™ couch (Elekta AB,
Stockholm, Sweden) and intensity modulated radiother-
apy (IMRT) was delivered using a multileaf collimator
with 4 mm leaf width (BeamModulator™, Elekta AB,
Stockholm, Sweden).
Other details of treatment planning and delivery were
not standardized between institutions and will therefore
be presented in the results part of the manuscript.
In order to correlate irradiation doses with clinical
results, biological equivalent doses in 2 Gy fractions
(EQD2) were calculated: an α/β-ratio of 10 Gy was as-
sumed for spinal metastases and an α/β-ratio of 2 Gy
for the spinal cord. The EQD2 was calculated using thelinear quadratic model (n = number of fractions; d = single
fraction dose):
EQD2 Gyð Þ ¼ n  d  d þ α=βð Þ= 2þ α=βð Þ
Imaging (CT, MRI or FDG-PET CT) was required
for assessment of local tumor control (LC) and local
failure was defined as tumor regrowth in the treated
volume according to institutional protocol. Progressive
clinical symptoms or pain without local tumor recur-
rence in imaging were not sufficient for definition of
local failure.
Pain at the treated vertebral level was categorized into
pain-free, mild-to-moderate pain and severe pain prior
to SBRT and at the last follow-up. If detailed information
as the visual analog scale was available, pain-free, mild-
to-moderate pain and severe pain were equivalent to
scores of 0, 1-5 and 6-10, respectively.
Statistical analyses were performed with Statistica X
(Statsoft, Tulsa OK), and all statistical tests were two-
sided. OS was evaluated per patient and all other end-
points per SBRT treatment. The Pearson chi-square/
Fisher’s Exact test and Kruskal-Wallis ANOVA were
used to compare categorical and continuous variables
between groups, respectively. Receiver Operating Char-
acteristics (ROC) curves were used to test prognostic
factors (irradiation dose) in predicting outcome, with
their performances measured based on the area under
the ROC curve. Estimated likelihood of events was cal-
culated using the Kaplan Meier method with start of
follow-up on the last day of SBRT treatment. The log-
rank test was used to compare differences between
curves in univariate analysis. Multivariate analysis was
performed using Cox-proportial Hazard method with
backward exclusion of non-significant variables; all
variables, which were statistically significant in the
univariate analysis, were included into the multivariate
analysis. A p-value of ≤0.05 was considered statistically
significant.
Results
Patient and treatment characteristics
Patient characteristics and characteristics of the treated
vertebral metastases are listed in Table 1. Inter-institutional
variability in patient selection criteria is illustrated in
Figure 1. The majority of patients presented with a good
performance status prior to SBRT (median Karnofsky
performance status 90). About one quarter of the pa-
tients were treated for a solitary vertebral metastasis
without further evidence of malignancy; additional bone
and visceral metastases were present in 62.9% and 42.3%
of the patients, respectively. Patients were free from epi-
dural disease extension in 41.8% (Bilsky score 0). Lesions
had an osteolytic component in 72.3% resulting in a
Table 1 Patient (n = 301) and lesion (n = 387) characteristics;
percentages are given per SBRT treatment
Characteristic Median Range Proportion (%)
Age (years) 61.3 9 – 91
Performance status 90 40 – 100
Sex (male) 55.1






Pain prior to SBRT
No 18.2
Yes 81.8
Solitary metastasis (yes) 23.0
Systemic disease considered as
controlled prior to SBRT (yes)
32.0
Cancer treated with curative intend
at primary diagnosis (yes)
67.7
Additional bone metastasis (present) 62.9
Visceral metastases (present) 42.3
Bilsky Score 0 (yes) 41.8
Paraspinal involvement of spine
metastasis (yes)
44.8
Osteolytic component of spine
metastasis (yes)
72.3
Compression fracture of spine
metastasis (yes)
19.8
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vertebra in 19.8%.
Treatment characteristics are summarized in Table 2.
A dedicated MRI and FDG-PET were used for target and
organ-at-risk definition in 85% and 18%, respectively.
Patients were immobilized using the BodyFix™ (Elekta
AB, Stockholm, Sweden) system (80.6%), a thermoplastic
mask (11.9%), a combination of both (3.5%) or other de-
vices (4%). Step-and-shoot IMRT was practiced in 96% of
all cases, and an anatomical target volume concept was
used in the majority of the cases (61%) [12]. A median of
one vertebrae (1-6) in one single target volume was
treated with median 3 irradiation fractions (1-20) to a
median prescription dose of 24 Gy (10 – 60 Gy). The
spinal cord, thecal sac and spinal canal formed the basis
for generation of the planning risk volume (PRV-SC) in
33.4%, 22.3% and 42.3%, respectively, and a PRV mar-
gin of 1-2 mm was used in 85% of the cases. The max-
imum point dose to the PRV-SC was median 10 Gy
(maximum 65 Gy). After calculation of 2 Gy equivalent
doses, 90% of all SBRT treatments were performed withprescription PTV doses and maximum PRV-SC doses of
27-65 Gy (EQD210) and 5-59 Gy (EQD22), respectively.
Variability of doses to the PTV and PRV-SC and the associ-
ation between PTV and PRV-SC doses are illustrated in
Figure 2.
Clinical outcome in the total patient population
The median follow-up was 11.8 months (0-105 months),
median OS was 19.5 months; one-year and two-years
OS were 64.9% and 43.7% (Figure 3), respectively. Uni-
variate analysis was performed for patient and treatment
factors associated with OS and significant parameters
were included into multivariate analysis. The follow-
ing characteristics were significantly associated with
worse OS: male sex (p < 0.001; HR = 0.44), performance
status <90 (p < 0.001; HR = 0.46), presence of visceral me-
tastases (p = 0.007; HR = 0.50), uncontrolled systemic dis-
ease (p = 0.007; HR = 0.45), >1 vertebra treated with SBRT
(p = 0.04; HR = 0.62).
LC was assessed using CT (25.4%), MRI (63.2%), FDG
PET (1.2%) or FDG PET-CT (10.2%); follow-up was too
short for analysis of local tumor control in 15%. One-
year and two-years LC were 89.9% and 83.9% (Figure 4),
respectively. Median time to development of local failure
was 9 months (1 – 55 months).
Univariate analysis was performed for patient and
treatment factors associated with local tumor control
and significant parameters were included into multivari-
ate analysis. The following characteristics were signifi-
cantly associated with worse outcome: interval between
primary diagnosis of cancer and SBRT of ≤30 months
(p = 0.01; HR = 0.27) and histology of primary disease
(NSCLC, renal cell cancer, melanoma, other) (p = 0.01;
HR = 0.21).
Prior to SBRT, patients were pain-free, suffered from
mild/moderate pain and severe pain in 18.2%, 64.9% and
16.9%, respectively. Detailed pain response at the treated
spinal level after a median follow-up of 11.5 months is
illustrated in Figure 5. Patients being pain-free, suffering
from mild/moderate and severe pain prior to SBRT were
pain-free at the time of the last clinical assessment in
76.8%, 56.3% and 43.8%, respectively. After uni- and
multivariate analyses, no patient or treatment charac-
teristic was significantly associated with improved pain
control.
Acute toxicity was mild in the majority of the patients:
grade 3 toxicity was observed in only 2 patients (Table 3).
Median follow-up for assessment of long-term toxicity
was 11.5 months, maximum 105 months. Progressive of
new vertebral compression fractures were diagnosed in
30 cases (7.8%), of which the fracture was newly devel-
oped after SBRT in 14 cases (3.6%) and progressive after
SBRT in 16 cases (4.1%). No case of radiation-induced
myelopathy (RIM) was observed.
Figure 1 Inter-institutional variability in patient characteristics.
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SBRT fractions
Patient characteristics and clinical outcome were com-
pared between SBRT with 1-5 fractions (n = 352) and
hypo-fractionated SBRT with 6-20 fractions (n = 35).
Hypo-fractionated SBRT was practiced in patients, who
had received palliative chemotherapy prior to SBRT lessTable 2 SBRT treatment (n = 387) characteristics
Characteristic Median Range Proportion (%)
Number of vertebras treated in
one target volume
1 1 – 6
Number of vertebras treated in
one target volume n = 1
70.4
Number of vertebras treated in
one target volume n = 2–3
24.7
Number of vertebras treated in
one target volume n = 4–6
4.9
Treatment fractions 3 1 – 20
Treatment fractions n = 1 39.5
Treatment fractions n = 2–5 51.4
Treatment fractions n = 6–20 9.1
Prescription dose (Gy) 24 8 – 60
PTV (cm3) 34 0.8 – 721
Max. point dose PRV spinal cord 10 2 – 65
Prescription dose (EQD2/10 Gy) 37.7 12 – 81
Max. point dose PRV spinal cord
(EQD2/2 Gy)
22.4 2 – 112frequently (17% vs 61%; p < 0.001) and who suffered from
pain less frequently (69% vs 84%; p = 0.03); all other pa-
tient characteristics were not statistically different. Meta-
static lesions treated with hypo-fractionated SBRT were
osteolytic more frequently (94% vs 70%; p = 0.001), were
characterized by a compression fracture prior to SBRT
more frequently (37% vs 18%; p = 0.01) and had a distri-
bution with higher Bilsky scores (p < 0.001). Irradiation
doses were significantly higher in patients treated with
hypo-fractionated SBRT: EQD210 PTV prescription dosesFigure 2 Distribution and correlation between PTV prescription
dose (EQD210) and maximum dose to the PRV-SC (EQD22);
results are shown for SBRT delivered in 1 fraction (1 FX), 2-5
fractions (2-5 FX) and 6-20 fractions (6-20 FX).
Number at risk
282 192 135 87 58 40 28 16 8












Figure 3 Overall survival analyzed per patient: Kaplan Meier
Curve with 95% confidence interval.
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and EQD22 maximal PRV spinal cord doses were 54 Gy
and 23 Gy (p < 0.001), respectively. In terms of clinical
outcome, median OS was 19 months and 20 months after
SBRT with <5 and 6-20 SBRT fractions (p = 0.89), re-
spectively. Local tumor was not different as well: two year
LC was 84% and 82% (p = 0.4), respectively. The develop-
ment of new fractures after SBRT was not correlated with
the number of SBRT fractions.
Discussion
This is the largest study reporting detailed data regarding
patient selection criteria, clinical practice and outcome of
spine SBRT in a multi-institutional environment. Sub-
stantial variability was observed in major aspects of spine
SBRT, despite the fact that nearly identical linac-based
SBRT technologies were utilized at all eight participating
institutions. This inter-institutional variability is mostNumber at risk
330 218 134 85 58 34 24 14 8













Figure 4 Local tumor control analyzed per treated lesion:
Kaplan Meier Curve with 95% confidence interval.likely explained by similar variability of SBRT practice in
the literature and the lack of clearly established patient
selection criteria and practice guidelines [13]. Results
of our study may therefore be considered as represen-
tative for current spine SBRT practice in the radiotherapy
community.
Whereas some centers explicitly selected patients with
long life expectancy for their spine SBRT practice, this
was not done by other institutions. The proportion of
patients free from visceral metastases prior to SBRT
ranged between 31.6% and 73.8% and oligomatastatic
disease was stated as the primary reason for SBRT in
between 23.7% and 100% of institutional cases. Similar
variability was observed for relevant treatment charac-
teristics. Fractionation ranged from single-fraction radio-
surgery to hypo-fractionated SBRT; one institution
treated the majority of their cases with 20 fractions,
which is not considered as SBRT based on the US SBRT
definition. However, treatment was planned and delivered
with identical accuracy as single fraction radiosurgery and
the fractionation of 20 × 3 Gy equates to a radiosurgical
dose of >23 Gy rendering this approach highly biologically
active [14].
Despite this variability in patient and treatment char-
acteristics, toxicity was minimal in this study. Most
importantly, no single case of RIM was observed. The
average time to development of RIM after conventional
radiotherapy is approximately 18 months [15]. Gibbs
et al. reported the largest study of six RIM cases in 1075
spine SBRT cases [9]: their 6 months time interval to
development of RIM appears shorter compared to
conventional radiotherapy. Follow-up was longer than
6 months and 18 months in 192 and 87 of our patients,
respectively, indicating a sufficiently long follow-up for
reliable analysis of RIM. The absence of RIM in our study
is especially encouraging as epidural disease with a Bilsky
score of >0 was present in 58% of our patients [16]. The
absence of RIM maybe explained by several safety mea-
sures, which were consistently practiced in our patient
cohort: 1) use of the PRV concept for the spinal cord,
2) maximum EQD22 doses to the PRV spinal cord ≤60 Gy
in >95% of the cases, 3) daily volumetric image-guidance
with online correction of set-up errors in six degrees of
freedom and 4) use of customized patient immobilization
for minimization of intra-fractional patient motion. These
measures might therefore be recommended for safe prac-
tice of spine SBRT.
Vertebral compression fractures were observed in only
7.8% of the treatments and half of them were progressive
fractures, which existed prior to SBRT. Compression
fractures are more frequently described in the literature
with rates of 11-39% [11,17,18]. Based upon these limited
data available, very high single fraction doses >20 Gy
appear to be associated with compression fractions, and
Figure 5 Pain response depending on the pre-SBRT pain score.
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study: only 22/387 cases were treated with such high
single fraction doses.
There is some controversy whether or not the in-
creased cost and workload associated with SBRT is ap-
propriate in the palliative setting of vertebral metastases
[19]. Indeed, OS is short in unselected patients treated
with conventional radiotherapy for painful vertebral me-
tastases: Mizimoto et al. reported a median OS of only
5.9 months in 544 patients [20] and van der Linden re-
ported a median OS of 7 months in a cohort of 342 pa-
tients, who were randomized between a single fraction
of 8 Gy and 6 × 4 Gy [21].
However, a substantially longer OS of median 19.5 months
was observed in the current study. Based on the fact
that conventional radiotherapy achieves pain control
only for the short duration of half a year [22-25], the
majority of the patients in this study were at risk for
recurring pain if conventional radiotherapy would have
been performed. It is also important to put this favor-
able overall survival rate into the perspective of locally
advanced NSCLC for example, where median OS is of
similar magnitude despite aggressive multimodal treat-
ment with curative intent [26,27].Table 3 Absolute number of patients where acute toxicity
was assessed and proportion of patients with grade 0-3
toxicity
Dermatitis Dysphagia Pain
Toxicity assessment available (n) 281 283 304
Grade 0 (%) 96.1 89.8 83.9
Grade 1 (%) 3.9 9.5 9.6
Grade 2 (%) 0 0.7 5.9
Grade 3 (%) 0 0 0.7OS varies substantially between studies using SBRT for
treatment of vertebral metastases. Favorable OS was re-
ported by Wang et al. with a median OS of 23 months
in 149 patients, where SBRT was used as primary treat-
ment and re-irradiation in a prospective phase II study
[7]. Median OS was as long as 30 months in 61 patients
treated with single fraction radiosurgery in a phase I/II
study [28]. Whether the favorable OS in this study and
the studies above is a result of the applied patient selec-
tion criteria or whether SBRT in an oligometastatic dis-
ease setting contributes to prolonged OS remains to be
evaluated. In contrast, Amdur et al. reported a 1-year
OS of only 25% in 25 patients treated within a phase II
study of single fraction radiosurgery [29]; Schipani et al.
reported a median OS of 8 months [30], Heron et al. re-
ported a median OS of 13 months [31]. A recursive par-
titioning analysis to predict OS was performed by Chao
et al., and the three factors of age, Karnofsky perform-
ance status and the time from primary diagnosis to
SBRT allowed differentiation of median OS between
2.4 months and 21.1 months [32]. In our study, mulit-
variate analysis identified several clinical parameters,
which were correlated with OS: gender, performance
status, presence of visceral metastases, uncontrolled sys-
temic disease, number of involved vertebras. These fac-
tors might help in the selection of patients with long life
expectancy for SBRT, but validation is required.
In this context of favorable OS, long-term local tumor
control was observed with actuarial rates of 89.9% and
83.9% at one and two years, respectively. This is in
agreement with other reports of spine SBRT, where
long-term local tumor control was achieved in >80% of
the cases [28,31,33-37]. Histology was significantly cor-
related with local tumor control and worse outcome
was observed in histologies known to be less radiosen-
sive: NSCLC, renal cell cancer and melanoma. A similar
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other studies [28,33].
A dose-response relationship was expected for achieve-
ment of LC, but such correlation was not observed. Pre-
scribed physical doses and biological effective doses were
not correlated with LC. Additionally, maximum doses to
the PRV spinal cord and pre-SBRT Bilsky score were not
significant as well, factors which should be correlated
with minimum PTV doses [33,38]. Several but not all
studies [28,34] reported that higher SBRT do result in
better LC, but there is no consensus about the detailed
dose and fractionation. Laufer et al. reported improved
outcome after high-dose (median total dose 27 Gy in 3
fractions) compared to low dose SBRT (median total dose
30 Gy in 5 or 6 fractions) [33]. Al-Omair et al. described
better LC after 18–26 Gy in 1–2 fractions compared to
18–40 Gy in 3–5 fractions [38]. In contrast, LC was bet-
ter after multiple-fraction compared to single fraction
SBRT in the study by Heron et al. [31]. Lovelock et al.
not only evaluated prescribed doses but performed a
more detailed dosimetrical analysis and minimum PTV
doses >15 Gy were significantly associated with better LC
[35]. Based on potential variability in the method of dose
prescription in this multicenter study, a detailed dosime-
trical analysis similar to Lovelock et al. is currently
underway. Additionally, radiological assessment of local
tumor control or tumor recurrence is difficult in many
cases and has been analyzed systematically only very re-
cently [39]; this lack of established criteria for local tumor
control might influence our multicenter analysis as well.
Finally, long-term LC was found to be associated with
long-term pain control. The high rates of complete pain
response ranging between 77% and 44% (depending on
the pre-SBRT pain score) appear promising compared to
complete pain response rates of only 25-40% after con-
ventional palliative radiotherapy [22-25]. Unfortunately,
the retrospective nature of this study did not allow for a
longitudinal pain assessment as well as analysis of pain
medication.
Strengths of this study include the large number of
387 SBRT treatments performed at eight experienced
international centers. A homogeneous patient cohort of
primary SBRT excluding re-irradiated patients and ex-
cluding patients treated for symptomatic spinal cord
compression was analyzed. All patients were treated with
linac-based SBRT using identical equipment. Follow-up
was sufficiently long with a median of 11.7 months.
Weaknesses of this study are the retrospective nature of
our multi-institutional analysis.
Conclusions
Linac based SBRT for vertebral metastases was deter-
mined to be safe in this multi-institutional environment
with no case of radiation-induced myelopathy. Use ofthe PRV concept for the spinal cord, maximum EQD22
doses to the PRV spinal cord ≤60 Gy, daily volumetric
image-guidance with online correction of set-up errors
in six degrees of freedom and the use of customized pa-
tient immobilization are recommended measures for
safe SBRT practice. In a patient cohort with favorable
OS, SBRT achieved high rates of long-term local tumor
control, which appears better compared to conventional
radiotherapy alone.
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